reference/18042803

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18042803

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	1066
issn	1528-0020 0006-4971
issueIdentifier	3
pageRange	1060-1066
publicationName	Blood
startingPage	1060
bibliographicCitation	Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01;111(3):1060–6. doi: 10.1182/blood-2007-06-098061. PMID: 17962510.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6d00d3aba027043e0cfebb59b17c883 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d364474d375c00a5173abc2ddf6434c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63f5936617fa815f6defe56b9bacb796 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_233018d328f93fcdf62e4fd49cb971d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc866d924ceedcfe2659b91011f55bfc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6166c3becfdc5646a5f63f3043c1fa8c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bfb887a90f53a9080cbc6c09a6adbad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8c1de7da4deb440ed2ecc8697edce38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6ee9dfbf434a342882c6ff2568b63d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_06a77a540571be84a1b339b869de430f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e605c269adda7e5090582abbca5a213a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f34b9ce3e1ab085bc75f5367ec33606 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f70a619fdfa94b5c4f72395e7a3b07c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_790a5fce774973cab12cb7ff51b01fa2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_07101db9d13d391a70088a61c1534fcb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d494a44d256da821a925cd86492c51e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d55f069e47920537e48fd94469539cf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4190883552be9e16fc03bddc09e5f0ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9fdcd8c5dd98284e9d042b8f3d798dbe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_552eba5c8f4f3d6ec552b9a98d3e7bea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30f88c7bb9350044577aa4a3b2f07af5
date	2008-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/17962510 https://doi.org/10.1182/blood-2007-06-098061
isPartOf	https://portal.issn.org/resource/ISSN/0006-4971 https://portal.issn.org/resource/ISSN/1528-0020 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
discusses	http://id.nlm.nih.gov/mesh/M0010429 http://id.nlm.nih.gov/mesh/M0010420 http://id.nlm.nih.gov/mesh/M0010739 http://id.nlm.nih.gov/mesh/M0527853 http://id.nlm.nih.gov/mesh/M0288128 http://id.nlm.nih.gov/mesh/M0007520
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D056572 http://id.nlm.nih.gov/mesh/D004791Q000627 http://id.nlm.nih.gov/mesh/D009190Q000473 http://id.nlm.nih.gov/mesh/D006877Q000627 http://id.nlm.nih.gov/mesh/D007938Q000188 http://id.nlm.nih.gov/mesh/D007938Q000473 http://id.nlm.nih.gov/mesh/D009190Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006655Q000378 http://id.nlm.nih.gov/mesh/D006877Q000009 http://id.nlm.nih.gov/mesh/D064420 http://id.nlm.nih.gov/mesh/D006877Q000008 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D015972 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D020869 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D017321 http://id.nlm.nih.gov/mesh/D004361 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006657Q000378 http://id.nlm.nih.gov/mesh/D007938Q000235 http://id.nlm.nih.gov/mesh/D000107 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000077337 http://id.nlm.nih.gov/mesh/D007938Q000201 http://id.nlm.nih.gov/mesh/D009190Q000201
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9860 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8560 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129625394 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129552408

Total number of triples: 95.